Taguchi Tetsuya
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine.
Clin Calcium. 2011 Mar;21(3):429-38.
In metastatic breast cancer the most common metastatic site is bone. Skeletal-related events (SREs) as well as bone pain are well-known characteristics of bone metastasis. Activation of osteoclast is the most important mechanism for the progression of bone metastasis. To treat bone metastasis, not only administration of antitumor drug but also inhibition of osteoclast activity should be required. Bisphosphonates, as potent inhibitors of osteoclast function, reduce the morbidity of metastatic bone disease, decrease the prevalence of SREs, and improve control of bone pain. Molecular targeted agents which inhibit maturity and activity of osteoclast are under development, and some effectiveness has been proved in clinical trials. Long-term survival just like good control of a symptom is expected in future by using new drugs specific to bone metastasis as part of multidisciplinary approach.
在转移性乳腺癌中，最常见的转移部位是骨骼。骨相关事件（SREs）以及骨痛是骨转移的众所周知的特征。破骨细胞的激活是骨转移进展的最重要机制。治疗骨转移不仅需要给予抗肿瘤药物，还需要抑制破骨细胞活性。双膦酸盐作为破骨细胞功能的有效抑制剂，可降低转移性骨病的发病率，降低SREs的发生率，并改善骨痛的控制。抑制破骨细胞成熟和活性的分子靶向药物正在研发中，并且在临床试验中已证明有一定疗效。通过使用针对骨转移的新药作为多学科方法的一部分，有望在未来实现长期生存，就像对症状的良好控制一样。
